In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year ...

Thomas W. LeBlanc, MD, MA, discusses how existing challenges in treatment choices for low-risk myelodysplastic syndromes ...

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring early-line and maintenance use.

The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with ...

The FDA has issued a complete response letter to the biologics license application seeking the approval of tabelecleucel for ...

Acalabrutinib with bendamustine and rituximab is now an FDA-approved treatment for patients with previously untreated mantle ...

Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated ...

Christina Henson, MD, discussed some of the current imaging guidelines in head and neck cancer, with a focus on extranodal extension.

Axatilimab has gained FDA approval in 9 mg and 22 mg vials, expanding treatment options for patients with chronic GVHD after ...

The FDA has approved the investigational new drug application of 225Ac-SSO110, allowing for the start of a phase 1/2 trial in ...

During a Case-Based Roundtable® event, Jean A. Yared, MD, moderated a discussion on the approach to CAR T-cell therapy for a ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...